Combined K1/SFB treatment allowed up to a 6.7-fold reduction in the concentration of sorafenib, with tumor reduction accompanied by reduced phosphorylation and inhibition of the RAF/MAPKK/ERK pathway. This evidence concerns the gene KRT1 and neoplasm.